Fecal Transplant Therapy Market Report 2026

The fecal transplant therapy market size has grown strongly in recent years. It will grow from $2.15 billion in 2025 to $2.28 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to documented efficacy in recurrent cdi treatment, increasing hospital awareness of microbiome therapies, expansion of gastroenterology specialty services, availability of basic stool preparation technologies, early-stage clinical trials.

The fecal transplant therapy market size is expected to see strong growth in the next few years. It will grow to $2.87 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing diversification of disease indications, rising demand for regulated and standardized products, expansion of outpatient fmt procedures, growing investment in microbiome therapeutics, advancements in automated stool processing systems. Major trends in the forecast period include increasing clinical adoption of stool-based therapies, rising development of capsule and suspension formats, growing exploration of neurological and metabolic indications, expansion of in-hospital fmt programs, enhanced emphasis on safety and standardization.

The rising prevalence of inflammatory bowel disease (IBD) is expected to drive the growth of the fecal transplant therapy market in the coming years. IBD is a chronic inflammation of the gastrointestinal tract, encompassing conditions such as Crohn's disease and ulcerative colitis. The increase in IBD cases is linked to higher consumption of processed foods, frequent or inappropriate antibiotic use, improved hygiene, and reduced exposure to infectious agents during childhood. Fecal transplant therapy works to restore a healthy gut microbiota, which can help reduce inflammation and improve symptoms in patients with IBD, potentially influencing disease management and progression. For example, in June 2023, Crohn's and Colitis Canada, a non-profit organization, reported that the number of individuals living with IBD in Canada is expected to rise from 322,600 in 2023 to 470,000 by 2035. Consequently, the growing prevalence of IBD is fueling the fecal transplant therapy market.

Companies in the fecal transplant therapy market are focusing on innovative microbiota-based therapies, including pill forms of fecal microbiota transplantation (FMT), to improve patient compliance and expand accessibility. The pill-based FMT therapy contains encapsulated live bacteria derived from donor feces, designed for oral administration to replenish healthy gut bacteria and support intestinal health. For instance, in April 2023, Seres Therapeutics Inc., a US-based biotechnology company, and Nestlé Health Science S.A., a Switzerland-based healthcare firm, launched VOWST. Delivered as capsules, VOWST offers a convenient, non-invasive option to prevent recurrent Clostridioides difficile infection (rCDI) in adults after antibacterial treatment. Unlike traditional FMT, which transfers whole stools, VOWST uses live bacterial spores from multiple Firmicute species sourced from healthy human donors to help restore the gut microbiome.

In September 2024, Metagen Therapeutics Inc., a Japan-based biotechnology startup, partnered with JSR Corporation to establish an investigational-drug manufacturing facility for microbiome medicines, including oral FMT drugs. Through this partnership, Metagen Therapeutics and JSR aim to initiate clinical trials for oral FMT therapies, expand patient access to microbiome-based treatments, improve manufacturing and quality control, and accelerate the development of therapies for conditions such as ulcerative colitis. JSR Corporation, a Japan-based materials and life-sciences company, provides expertise in advanced materials innovation and biopharmaceutical manufacturing support.

Major companies operating in the fecal transplant therapy market are Mayo Clinic, Mount Sinai Health System Inc., Northwestern Medicine, NYU Langone Health, Michigan Medicine, UCLA Health, Duke University Health System Inc., Stanford Health Care, Ferring Pharmaceuticals, Cincinnati Children's Hospital Medical Center, Emory Healthcare, Cambridge University Hospitals NHS Foundation Trust, Hamilton Health Sciences Corporation, Brigham and Women's Faulkner Hospital Inc., Rebiotix Inc., Seres Therapeutics Inc., UPMC Hillman Cancer Center, OpenBiome, Center for Digestive Disease, BiomeBank Incorporated, The Regents of the University of California.

North America was the largest region in the fecal transplant therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fecal transplant therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fecal transplant therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the fecal transplant therapy market by increasing costs of imported medical consumables, processing equipment, sterile containers, and diagnostic systems used in stool preparation and administration. Healthcare institutions in North America and Europe are most affected due to reliance on imported clinical supplies, while Asia-Pacific experiences higher setup costs for therapy programs. These tariffs are elevating treatment costs and limiting accessibility. However, they are also encouraging domestic production of medical consumables, localized therapy infrastructure, and innovation in cost-efficient fecal transplant delivery models.

The fecal transplant therapy market research report is one of a series of new reports that provides fecal transplant therapy market statistics, including fecal transplant therapy industry global market size, regional shares, competitors with a fecal transplant therapy market share, detailed fecal transplant therapy market segments, market trends and opportunities, and any further data you may need to thrive in the fecal transplant therapy industry. This fecal transplant therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Fecal transplant therapy, also referred to as fecal microbiota transplantation (FMT), is a medical procedure in which stool from a healthy donor is transferred into the gastrointestinal (GI) tract of a recipient. This therapy is primarily used to treat recurrent Clostridium difficile infections and other gut-related disorders. Its goal is to repopulate the patient’s gut with beneficial bacteria, thereby improving gut health and digestion.

The main methods of fecal transplant therapy include fecal enema, fecal bacteriotherapy, stool transplant, human probiotic infusion, and fecal transfusion. Fecal enema involves delivering donor stool directly into a patient’s colon via an enema to restore gut microbial balance. This therapy is used to manage conditions such as Clostridium difficile infection, autism, obesity, Parkinson’s disease (PD), diabetes mellitus, and other disorders. The primary end users of fecal transplant therapy are hospitals, specialty clinics, and other healthcare facilities.

The fecal transplant therapy market includes revenues earned by entities through donor screening and selection, stool processing and preparation, and post-procedure monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.